Phase I: Safety and Tolerance of Lactobactocillus reuteri in Adults

第一阶段:罗伊氏乳杆菌在成人中的安全性和耐受性

基本信息

项目摘要

DESCRIPTION (provided by applicant): The long-term goals of this laboratory are to elucidate mechanisms of intestinal disease in infants and children and to use basic science to identify rational treatments. Relevant to the mission of NIH, this proposal is designed as a pilot study that will generate and expand the base of in vivo data and direct future research on probiotic therapeutic interventions. Additionally, the investigators aim to utilize state-of-the science technologies to determine the constituents of complex gut microbiotia that are associated with and may contribute to colic, and to examine the impact of probiotics on the composition of the bowel flora. Colic is defined as crying and fussiness for > 3 hr daily for > 3 d weekly in a child < 3 months old. Currently, there is insufficient evidence supporting any specific treatment to relieve symptoms of infants with colic, with the possible exception of hypoallergenic formula. However, there is evidence that infants with colic produce too much hydrogen gas in the intestine and that their fussiness may be improved by daily administration of certain probiotic (health-promoting) bacteria. Recently, studies in adults with irritable bowel syndrome showed significant improvement with probiotic therapy. Our hypothesis is that infants produce more hydrogen gas because of a different colonic bacterial flora and that modification of this flora with Lactobacillus rhamnosus GG will alter gas production, thereby reducing the time these infants spend crying. We choose to study Lactobacillus rhamnosus GG, one of the two probiotic strains which has received the most investigation in babies with diarrhea. L. rhamnosus GG is FDA-approved and available over-the-counter in the U.S. Relevance to public health: Colic affects at least 8% of all infants. Our studies would not only provide evidence for whether oral L. rhamnosus GG helps reduce the number of minutes each day with colic; they would also provide evidence of a possible mechanism. Specifically, we will demonstrate if L. rhamnosus GG treatment of infants with colic who have excessive breath hydrogen levels will change the bacterial community in the colon and reduce fecal markers of inflammation. In the process, we will also demonstrate if cultivation-independent analyses of stool will reveal bacterial species associated with colic that were not previously recognized.
描述(由申请人提供):该实验室的长期目标是阐明婴儿和儿童肠道疾病的机制,并利用基础科学来确定合理的治疗方法。与NIH的使命相关,该提案被设计为试点研究,将产生和扩大体内数据的基础,并指导未来对益生菌治疗干预的研究。此外,研究人员的目标是利用科学技术来确定与绞痛相关并可能导致绞痛的复杂肠道微生物群的成分,并检查益生菌对肠道植物群组成的影响。 绞痛定义为< 3个月的儿童每天哭闹> 3小时,每周> 3天。目前,没有足够的证据支持任何具体的治疗,以减轻症状的婴儿绞痛,与可能的例外,低过敏性配方。然而,有证据表明,患有绞痛的婴儿在肠道中产生过多的氢气,并且他们的烦躁可以通过每天服用某些益生菌(促进健康)细菌来改善。最近,在成人肠易激综合征的研究显示,益生菌治疗显着改善。我们的假设是,由于不同的结肠细菌植物群,婴儿产生更多的氢气,并且用鼠李糖乳杆菌GG修饰该植物群将改变气体产生,从而减少这些婴儿哭泣的时间。我们选择研究鼠李糖乳杆菌GG,这是两种益生菌菌株之一,已收到最多的调查婴儿腹泻。L.鼠李糖GG是FDA批准的,在美国可以非处方购买。 与公共卫生的相关性:绞痛影响至少8%的婴儿。本研究不仅为L. rhamnosus GG有助于减少每天绞痛的分钟数;他们还将提供可能机制的证据。具体来说,我们将证明,如果L。rhamnosus GG治疗具有过量呼吸氢水平的绞痛婴儿将改变结肠中的细菌群落并减少炎症的粪便标记物。在这个过程中,我们还将证明,如果培养独立的粪便分析将揭示细菌物种与绞痛,以前没有认识到。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JON Marc RHOADS其他文献

JON Marc RHOADS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JON Marc RHOADS', 18)}}的其他基金

Road to discovery for combination probiotic BB-12 with LGG in treating autism spectrum disorder
益生菌 BB-12 与 LGG 组合治疗自闭症谱系障碍的发现之路
  • 批准号:
    10657357
  • 财政年份:
    2018
  • 资助金额:
    $ 22.83万
  • 项目类别:
Road to discovery for combination probiotic BB-12 with LGG in treating autism spectrum disorder
益生菌 BB-12 与 LGG 组合治疗自闭症谱系障碍的发现之路
  • 批准号:
    9766942
  • 财政年份:
    2018
  • 资助金额:
    $ 22.83万
  • 项目类别:
Road to discovery for combination probiotic BB-12 with LGG in treating autism spectrum disorder
益生菌 BB-12 与 LGG 组合治疗自闭症谱系障碍的发现之路
  • 批准号:
    10439571
  • 财政年份:
    2018
  • 资助金额:
    $ 22.83万
  • 项目类别:
Road to discovery for combination probiotic BB-12 with LGG in treating autism spectrum disorder
益生菌 BB-12 与 LGG 组合治疗自闭症谱系障碍的发现之路
  • 批准号:
    9969235
  • 财政年份:
    2018
  • 资助金额:
    $ 22.83万
  • 项目类别:
Safety and Effect of L. reuteri on Biomarkers of Inflammation in Healthy Infants
罗伊氏乳杆菌的安全性及其对健康婴儿炎症生物标志物的影响
  • 批准号:
    8650793
  • 财政年份:
    2012
  • 资助金额:
    $ 22.83万
  • 项目类别:
Safety and Effect of L. reuteri on Biomarkers of Inflammation in Healthy Infants
罗伊氏乳杆菌的安全性及其对健康婴儿炎症生物标志物的影响
  • 批准号:
    8304030
  • 财政年份:
    2012
  • 资助金额:
    $ 22.83万
  • 项目类别:
Effect of Lactobactocillus Rhamnosus GG on Colic Symptoms and Breath Hydrogen
鼠李糖乳杆菌 GG 对绞痛症状和呼气氢的影响
  • 批准号:
    7314788
  • 财政年份:
    2008
  • 资助金额:
    $ 22.83万
  • 项目类别:
Phase I: Safety and Tolerance of Lactobactocillus reuteri in Adults
第一阶段:罗伊氏乳杆菌在成人中的安全性和耐受性
  • 批准号:
    7920228
  • 财政年份:
    2008
  • 资助金额:
    $ 22.83万
  • 项目类别:
Phase I: Safety and Tolerance of Lactobactocillus reuteri in Adults
第一阶段:罗伊氏乳杆菌在成人中的安全性和耐受性
  • 批准号:
    8259339
  • 财政年份:
    2008
  • 资助金额:
    $ 22.83万
  • 项目类别:
MECHANISMS OF INTESTINAL CELL MIGRATION
肠细胞迁移的机制
  • 批准号:
    6381820
  • 财政年份:
    2000
  • 资助金额:
    $ 22.83万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.83万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 22.83万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 22.83万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 22.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 22.83万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 22.83万
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    $ 22.83万
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 22.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 22.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 22.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了